ArticleEJHaem2022

De-escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: A multicentral, open-label, prospective trial in China.

Jie Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.